Association of a dominantly inherited hyperphosphorylated paraprotein target with sporadic and familial multiple myeloma and monoclonal gammopathy of undetermined significance: a case–control study

Grass, Sandra; Preuss, Klaus‐Dieter; Ahlgrimm, Manfred; Fadle, Natalie; Regitz, Evi; Pfoehler, Claudia; Murawski, Niels; Pfreundschuh, Michael

doi:10.1016/s1470-2045(09)70234-7

Cited by 56 publications

(68 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…All patients with paratarg-7-specific paraproteins were carriers of a hyperphosphorylated modification of paratarg-7 (pP-7) (4), and the pP-7 carrier state is inherited in an autosomaldominant fashion (4). Besides paratarg-7, 10 additional paratargs were identified (5), for most of which hyperphosphorylation was shown to be a consistent finding and the most likely reason for chronic autoantigenic stimulation (6).…”

Section: Introductionmentioning

confidence: 99%

Sumoylated HSP90 is a dominantly inherited plasma cell dyscrasias risk factor

Preuss¹,

Pfreundschuh²,

Fadle³

et al. 2014

J. Clin. Invest.

Self Cite

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Sumoylated HSP90 is a dominantly inherited plasma cell dyscrasias risk factor

Preuss¹,

Pfreundschuh²,

Fadle³

et al. 2014

J. Clin. Invest.

Self Cite

View full text Add to dashboard Cite

“…Recent laboratory studies have identified specific antigenic targets associated with the development of MGUS and multiple myeloma. In a case-control study, Grass and colleagues proposed that hyperphosphorylation of partarg-7, a target of immunoglobulin A, M, and G (IgA, IgM, and IgG) paraproteins, may induce autoimmunity and thus be important in the pathogenesis of MGUS and/or multiple myeloma (47)(48)(49). Genetic analysis of eight families revealed that hyperphosphorylated paratarg-7 was inherited in a dominant manner, and carriers had an almost 8-fold increased risk of developing IgA or IgG MGUS and multiple myeloma (OR 7.9; 95% CI, 2.8-22.6; refs.…”

Section: Discussionmentioning

confidence: 99%

Prior Autoimmune Disease and Risk of Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma: A Systematic Review

McShane

Murray

Landgren

et al. 2014

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

Background: Several observational studies have investigated autoimmune disease and subsequent risk of monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma. Findings have been largely inconsistent and hindered by the rarity and heterogeneity of the autoimmune disorders investigated. A systematic review of the literature was undertaken to evaluate the strength of the evidence linking prior autoimmune disease and risk of MGUS/multiple myeloma.Methods: A broad search strategy using key terms for MGUS, multiple myeloma, and 50 autoimmune diseases was used to search four electronic databases (PubMed, Medline, Embase, and Web of Science) from inception through November 2011.Results: A total of 52 studies met the inclusion criteria, of which 32 were suitably comparable to perform a meta-analysis. "Any autoimmune disorder" was associated with an increased risk of both MGUS [n ¼ 760 patients; pooled relative risk (RR) 1.42; 95% confidence interval (CI), 1.14-1.75] and multiple myeloma (n>2,530 patients; RR 1.13, 95% CI, 1.04-1.22). This risk was disease dependent with only pernicious anemia showing an increased risk of both MGUS (RR 1.67; 95% CI, 1.21-2.31) and multiple myeloma (RR 1.50; 95% CI, 1.25-1.80).Conclusions: Our findings, based on the largest number of autoimmune disorders and patients with MGUS/multiple myeloma reported to date, suggest that autoimmune diseases and/or their treatment may be important in the etiology of MGUS/multiple myeloma. The strong associations observed for pernicious anemia suggest that anemia seen in plasma cell dyscrasias may be of autoimmune origin.Impact: Underlying mechanisms of autoimmune diseases, general immune dysfunction, and/or treatment of autoimmune diseases may be important in the pathogenesis of MGUS/multiple myeloma. Cancer Epidemiol Biomarkers Prev; 23(2); 332-42. Ó2014 AACR.

show abstract

“…28 It has also been suggested that chronic antigenic stimulation may play a role in multiple myeloma. 29 It is likely that other antigens, not yet identified, are involved in selection of the malignant clone. Epitope-mediated antigen prediction technology may identify antigens reacting with paraprotein antibodies.…”

Section: Immunoglobulin M Antibodies To Neural Antigensmentioning

confidence: 99%